Palm Beach, FL – (February 5, 2019) – Most know the phrase, “The Business of America is Business”, although that is not exactly what Calvin Coolidge actually said, it has aptly described the role of the United States in world commerce since World War II. What Coolidge actually said was: “the chief business of the American people is business.” And today we can morph that to the business of the American businesses is innovation and medical technology is an area where U.S. companies are at the forefront. A recent FORBES article says this about the size of the medical device market and the importance of innovators: “A disruptive market of $410 billion until 2023, changes dramatically with the entrance of small and medium size players, many of them rising up from the startup community.” An industry publication reports that: “The medical technology industry (commonly referred to as medical devices) consists of articles, instruments, apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for some health purpose. Active healthcare stocks in news today include: BioSig Technologies, Inc. (NASDAQ:BSGM), Medtronic plc (NYSE:MDT), Cardinal Health (NYSE:CAH), Abbott Laboratories (NYSE:ABT), Johnson & Johnson (NYSE:JNJ).
A strong example of thriving opportunity in the medical devices sector was illustrated in a recent article that echoes the importance of innovation: “ The Global Electrophysiology Market is expected to exceed more than $8.5 Billion by 2024 at a CAGR of 10.6%” and pinpoints a particular market niche that is showing rapid growth. “Electrophysiology is the branch of science which manages the investigation of electric movement in the human body… The development of the worldwide Electrophysiology market is driven by a few elements, the most essential of which is the technological advancements. Advancement of new devices are foreseen to fuel demand in the market.”
BioSig Technologies, Inc. (NASDAQ:BSGM) BREAKING NEWS – BioSig Technologies, a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company has appointed Mr. John Kowalski as Vice-President of Sales.
Mr. Kowalski brings to the Company over 30 years of experience in medical device sales, including over 20 years at Biosense Webster, a Johnson & Johnson company. Most recently, he served as Northeast Area Director, a role, in which he was responsible for leading six high-performing cardiac electrophysiology catheter and equipment market sales teams, consisting of 140 sales and clinical support employees. Mr. Kowalski was responsible for $175M disposables and system sales and has consistently exceeded area sales objectives. Having led U.S. strategic planning teams in his previous roles, Mr. Kowalski brings to BioSig proven track record in identifying key business growth opportunities within the cardiac electrophysiology market.
Mr. Kowalski is a holder of numerous Biosense Webster leadership awards, including a record 18-year Founders Club Award, and several “Area and Region of the Year” awards.
“John impressed us with his outstanding leadership skills and unparalleled knowledge of cardiac electrophysiology industry. Given John’s impressive accomplishments as a sales leader, we are confident that he is perfectly positioned to lead targeted market launch and grow our commercial capabilities for our innovative technology,” stated Mr. Kenneth Londoner, Chairman & CEO of BioSig Technologies, Inc.
“I am excited to lead the commercial launch of the PURE EP(tm) signal acquisition and processing system. I believe this innovative technology will enable improved diagnosis and treatment of cardiac arrhythmias and benefit millions of people who suffer from this debilitating illness,” commented Mr. Kowalski.
The Company announced that it received the 510(k) clearance for its PURE EP(tm) System on August 14, 2018. BioSig announced in November and December 2018 that it signed agreements to commence the first commercial use of the system at Texas Cardiac Arrhythmia Institute in Austin, Texas, and Mayo Clinic. BioSig signed a 10-year collaboration agreement with Mayo Clinic in March 2017 and announced a new research agreement focusing on development of additional advanced features and potential new applications of PURE EP(tm) System on November 13, 2018. Read this and more news for BSGM at: https://financialnewsmedia.com/news-bsgm
In other healthcare industry news of note:
Johnson & Johnson (NYSE: JNJ) recently announced the launch of its TECNIS Eyhance IOL for the treatment of cataracts in Europe. This next-generation monofocal intraocular lens (IOL) allows patients to experience high-quality vision at both intermediate and far distances. This is an important first for the monofocal IOL category, as today most lenses in the monofocal category only correct vision to help patients with cataracts see things at a distance, and thus do not improve the intermediate vision that is required for many important daily tasks.
“With the availability of TECNIS Eyhance IOL in Europe, we are proud to deliver another meaningful solution for patients with cataracts,” said Tom Frinzi, Worldwide President, Surgical, Johnson & Johnson Vision3. “We saw an opportunity to build upon the legacy of the TECNIS® Family of IOLs and the proven design of our 1-piece platform to reimagine what was possible with the standard aspheric monofocal IOL.”
Abbott Laboratories (NYSE: ABT) recently announced financial results for the fourth quarter and full year ended Dec. 31, 2018, and issued financial outlook for 2019. Full-year 2018 worldwide sales of $30.6 billion increased 11.6 percent on a reported basis and 7.3 percent on an organic basis.
In October, Abbott received U.S. FDA approval of its HeartMate 3™ left ventricular assist device as a destination (long-term use) therapy. In January 2019, Abbott announced U.S. FDA approval of its TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, a new catheter designed to help physicians accurately and effectively treat atrial fibrillation, a form of irregular heartbeat.
Medtronic plc (NYSE: MDT) recently announced the first U.S. patients treated with the Mazor X Stealth(TM) Edition for spine surgery following its recent commercial launch. The Mazor X Stealth Edition offers a fully-integrated procedural solution for surgical planning, workflow, execution and confirmation. The system was first used at Norton Healthcare in Louisville, Ky., and Reston Hospital Center in Reston, Va.
“It is rare that huge sectors of technology such as robotics and navigation merge into a sole platform as found in the Mazor X Stealth Edition. Combined, these may provide more predictable and reliable execution of our procedure workflows,” remarked Jeffrey Gum, M.D., orthopedic spine surgeon at Norton Leatherman Spine. “Computerized surgical planning, 3-D assessment of spine anatomy, robotic guidance and live navigation feedback are designed to provide a higher degree of accuracy throughout the surgical procedure.”
Almeida added, “Our ongoing business transformation will continue throughout 2019 as we prepare to launch new products, pursue high-value capital deployment opportunities and deliver on additional operational excellence initiatives. Our goal remains to drive top quartile performance for all stakeholders in line with our Mission to Save and Sustain Lives.”
Cardinal Health (NYSE:CAH) recently announced that Brian Rice will join the company as executive vice president, chief information officer and customer support services. Rice’s most recent role was senior vice president, chief information officer and global business services for Kellogg Company. In his new role at Cardinal Health, he will report to Mike Kaufmann, CEO of Cardinal Health.
“We are very excited to welcome a professional with Brian’s breadth of global experience to join our team at a time when technology is central to our business success,” said Kaufmann. “Brian’s expertise and achievements in identifying, implementing and running extremely complex, global information technology strategies and processes make him a perfect fit to lead Cardinal Health’s experienced and committed technology and customer services teams.”
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM has been compensated forty six hundred dollars for multiple day news coverage of the current press releases issued by BioSig Technologies, Inc. by the company. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Media Contact email: email@example.com – +1(561)325-8757